Skip to main content

Market Overview

Hoth Therapeutics Inks Research Pact For Critical Studies Of HT-006 Antibiotic


Hoth Therapeutics Inc (NASDAQ: HOTH) has entered into a Research Agreement with the University of Cincinnati Research Institute to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan.

  • HT-006 is under development as a potential treatment for multi-drug resistant bacterial lung infections, such as hospital-acquired pneumonia, cystic fibrosis, chronic obstructive pulmonary disease, and ventilator-associated pneumonia.
  • Hoth previously licensed the HT-006 technology for commercial evaluation from the Walter Reed Army Institute of Research.
  • The research plan includes critical antimicrobial in vitro characterization studies for HT-006 in alignment with the FDA's program for "antibacterial therapies.
  • The company says that this streamlined program allows for nonclinical animal studies to reduce clinical studies required for approval.
  • Price Action: HOTH gained 3.3% at $2.19 in market trading hours on the last check Wednesday.

Related Articles (HOTH)

View Comments and Join the Discussion!

Posted-In: antibioticsBiotech News Penny Stocks Health Care Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at